Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered β-catenin switch.

Jin Z, Wei W, Dechow PC, Wan Y.

Mol Endocrinol. 2013 Feb;27(2):325-35. doi: 10.1210/me.2012-1302. Epub 2012 Nov 30.

2.

Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF.

Stemig M, Astelford K, Emery A, Cho JJ, Allen B, Huang TH, Gopalakrishnan R, Mansky KC, Jensen ED.

PLoS One. 2015 Apr 15;10(4):e0123843. doi: 10.1371/journal.pone.0123843. eCollection 2015.

3.

MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.

Kim HN, Lee JH, Jin WJ, Ko S, Jung K, Ha H, Lee ZH.

Eur J Pharmacol. 2012 Sep 15;691(1-3):69-76. doi: 10.1016/j.ejphar.2012.07.034. Epub 2012 Jul 27.

PMID:
22846626
4.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
6.

Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.

Tsuji-Naito K.

Bioorg Med Chem. 2008 Oct 15;16(20):9176-83. doi: 10.1016/j.bmc.2008.09.036. Epub 2008 Sep 14.

PMID:
18823786
7.

Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG.

Xu S, Zhang Y, Liu B, Li K, Huang B, Yan B, Zhang Z, Liang K, Jia C, Lin J, Zeng C, Cai D, Jin D, Jiang Y, Bai X.

J Bone Miner Res. 2016 Jul;31(7):1320-33. doi: 10.1002/jbmr.2800. Epub 2016 Mar 4.

8.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

9.

Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.

Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.

Eur J Pharmacol. 2009 Nov 25;623(1-3):22-9. doi: 10.1016/j.ejphar.2009.09.025. Epub 2009 Sep 17.

PMID:
19766111
10.

RARγ is a negative regulator of osteoclastogenesis.

Green AC, Poulton IJ, Vrahnas C, Häusler KD, Walkley CR, Wu JY, Martin TJ, Gillespie MT, Chandraratna RA, Quinn JM, Sims NA, Purton LE.

J Steroid Biochem Mol Biol. 2015 Jun;150:46-53. doi: 10.1016/j.jsbmb.2015.03.005. Epub 2015 Mar 20.

PMID:
25800721
12.
14.

Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Cheng J, Liu J, Shi Z, Jules J, Xu D, Luo S, Wei S, Feng X.

J Interferon Cytokine Res. 2012 Jan;32(1):34-45. doi: 10.1089/jir.2011.0019. Epub 2011 Dec 5.

15.

Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.

Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.

Eur J Pharmacol. 2013 Sep 5;715(1-3):96-104. doi: 10.1016/j.ejphar.2013.06.002. Epub 2013 Jun 19.

PMID:
23791609
16.
17.

Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.

He L, Lee J, Jang JH, Lee SH, Nan MH, Oh BC, Lee SG, Kim HH, Soung NK, Ahn JS, Kim BY.

Bone. 2012 Jun;50(6):1207-13. doi: 10.1016/j.bone.2012.03.022. Epub 2012 Mar 28.

PMID:
22484180
18.

HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling.

Jin Z, Wei W, Huynh H, Wan Y.

Mol Endocrinol. 2015 May;29(5):730-8. doi: 10.1210/me.2014-1365. Epub 2015 Mar 20.

19.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

20.

RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.

Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M.

J Bone Miner Res. 2007 Oct;22(10):1612-20.

Supplemental Content

Support Center